ondasdechoque.org
PT-BR

Plantar heel pain / plantar fasciopathy · Randomized trial · 2026

How does shockwave compare with a steroid injection and radiofrequency for heel pain?

In this trial, heel pain fell from about 8 to about 3.5 out of 10 a year after three shockwave sessions, one a week. People treated with radiofrequency, a needle-based heat treatment, did better, ending at about 1.6. Those who had a steroid injection ended at about 3.

Radiofrequency did better at 12 months
people (62 feet) with heel pain
49
shockwave sessions, one a week
3
months of follow-up
12

Good to know: Some people had both feet treated, and each foot was counted.

Tütüncü MN, Sekizkardeş M, Şahin E, et al. BMC Musculoskeletal Disorders, 2026 · Read the paper ↗

What happened

Heel pain

0–10 pain scale · start and after 12 months

StartAfter 12 months

Pain fell in all three groups. After 12 months it was about 1.6 out of 10 with radiofrequency, 3 with a steroid injection and 3.5 with shockwave.
Show the numbers
GroupPeopleStartAfter 12 months
Shockwave—7.793.47
Radiofrequency—6.871.61
Steroid injection—8.13.05

The treatment

Shockwave

Shockwave, once a week for 3 weeks

ShockwavesThe paper doesn’t say whether radial or focused
Sessions
3, one a week
Pulses
2,000 per session
Strength
4.0bar · 15 per second
Numbing
Not mentioned
Device
BTL-5000 SWT
Everyone also got
Anti-inflammatory tablets for five days, plus ice and stretching advice

Compared with: A steroid injection, or radiofrequency (a needle-based heat treatment)

Settings are what each study used, not a prescription.

Who took part

49 people (62 feet) with heel pain that had not settled with other care.

Side effects

The study does not report side effects.

All the numbers and the full appraisal
FROM THE FULL PAPER

The results, in numbers.

Adults with chronic plantar heel pain refractory to conservative care; analyzed per foot. Narrative reports 20 CSI feet/18 patients, 19 ESWT feet/15 patients, and 23 radiofrequency feet/16 patients; Table 2 sex totals conflict.

Corticosteroid injection

The study analyzed feet, and some participants contributed both feet. Foot counts agree between the Results prose and Table 2 (20 corticosteroid, 19 ESWT, 23 radiofrequency), but Table 2's female/male figures sum to those foot counts rather than to the narrative patient counts (18, 15, 16); participant count is left null.

Extracorporeal shock-wave therapy

The study analyzed feet, and some participants contributed both feet. Foot counts agree between the Results prose and Table 2 (20 corticosteroid, 19 ESWT, 23 radiofrequency), but Table 2's female/male figures sum to those foot counts rather than to the narrative patient counts (18, 15, 16); participant count is left null.

Radiofrequency thermal lesioning

The study analyzed feet, and some participants contributed both feet. Foot counts agree between the Results prose and Table 2 (20 corticosteroid, 19 ESWT, 23 radiofrequency), but Table 2's female/male figures sum to those foot counts rather than to the narrative patient counts (18, 15, 16); participant count is left null.

Visual Analogue Scale pain score1 reported outcome
01
12 months after treatment; baseline before treatment

Visual Analogue Scale pain score

Visual Analogue Scale (VAS), 10 cm VAS points

BaselineFollow-up
Corticosteroid injection
3.05
Extracorporeal shock-wave therapy
3.47
Radiofrequency thermal lesioning
1.61
010 VAS points
means
GroupnBaselineFollow-up
Corticosteroid injection—8.1 (SD 1.373)3.05 (SD 1.432)
Extracorporeal shock-wave therapy—7.79 (SD 1.084)3.47 (SD 2.01)
Radiofrequency thermal lesioning—6.87 (SD 2.007)1.61 (SD 0.839)

SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.

REPORTED COMPARISON TESTp <0.001

Radiofrequency had lower pain score than ESWT (reported difference 1.86 points; p<0.001).

Post-hoc comparison as reported by authors

Radiofrequency had lower pain score than ESWT (reported difference 1.86 points; p<0.001). Radiofrequency had lower pain score than corticosteroid injection (reported difference 1.44 points; p=0.006).

Analysis details and source

Group means and SDs are reported by foot; per-arm analyzed foot counts are not provided in the outcome table. Bilateral feet from some participants were treated as independent units; no clustering adjustment was reported.

Foot Function Index total score1 reported outcome
02
12 months after treatment; baseline before treatment

Foot Function Index total score

Foot Function Index (FFI), total FFI points

means
GroupnBaselineFollow-up
Corticosteroid injection—133.4 (SD 24.4053)50.25 (SD 23.5816)
Extracorporeal shock-wave therapy—122.579 (SD 29.1725)56.737 (SD 33.7505)
Radiofrequency thermal lesioning—97.783 (SD 38.3559)27.043 (SD 12.4261)

SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.

REPORTED COMPARISON TESTp = 0.001

Radiofrequency was better than ESWT (p=0.001) and corticosteroid injection (p=0.008), per the narrative post-hoc results.

Post-hoc comparison as reported by authors

Radiofrequency was better than ESWT (p=0.001) and corticosteroid injection (p=0.008), per the narrative post-hoc results.

Analysis details and source

Group means and SDs are reported by foot; per-arm analyzed foot counts are not provided in the outcome table. Bilateral feet from some participants were treated as independent units; no clustering adjustment was reported.

Roles and Maudsley score1 reported outcome
03
12 months after treatment; baseline before treatment

Roles and Maudsley score

Roles and Maudsley score Score points

means
GroupnBaselineFollow-up
Corticosteroid injection—3.5 (SD 0.6882)1.7 (SD 0.5712)
Extracorporeal shock-wave therapy—3.526 (SD 0.513)1.895 (SD 0.9366)
Radiofrequency thermal lesioning—2.696 (SD 0.5588)1.174 (SD 0.3876)

SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.

REPORTED COMPARISON TESTp = 0.002

Radiofrequency was reported superior to both ESWT and corticosteroid injection at 12 months (p=0.002); scale direction is not stated in the source, so no scale range or direction is assigned here.

Post-hoc comparison as reported by authors

Radiofrequency was reported superior to both ESWT and corticosteroid injection at 12 months (p=0.002); scale direction is not stated in the source, so no scale range or direction is assigned here.

Analysis details and source

Group means and SDs are reported by foot; per-arm analyzed foot counts are not provided in the outcome table. Bilateral feet from some participants were treated as independent units; no clustering adjustment was reported.

How treatment was delivered
ESWT device and modality

BTL-5000 SWT; focused modality is not stated explicitly in the protocol; ultrasound-guided plantar heel application.

ESWT settings and schedule

15 Hz, 2,000 pulses, 4.0 bar; three sessions, one week apart. No bar-to-energy conversion is made.

Corticosteroid injection

Ultrasound-guided medial injection: 1 mL betamethasone 40 mg/mL plus 2 mL bupivacaine 5 mg/mL.

Radiofrequency lesioning

Single session; NeuroTherm JK4A; 22G, 10-cm cannula; 50 Hz; 90°C for 90 seconds, repeated at up to three pain sites; local entry anesthetic 1 mL lidocaine 2%.

Co-interventions

All groups received NSAIDs for five days and advice for ice and stretching; no activity/weight-bearing restriction recommended.

HARMS & TOLERABILITY

No structured adverse-event counts are reported. The Discussion names known corticosteroid risks, including fat-pad atrophy and plantar-fascia rupture, but does not give study-specific arm counts.

LIMITS OF THE ANALYSIS

Authors report no placebo arm, no double blinding, and subjective outcomes.

Bilateral feet from some participants were analyzed as independent units without adjustment for intra-person clustering.

Radiofrequency group had longer symptom duration at baseline; authors note possible confounding.

Patient counts in Results prose and Table 2 are inconsistent; exact arm participant totals remain unresolved.

No outcome beyond 12 months was assessed.

Findings checked against the full source by a separate automated reviewer.

Limitations noted by the reviewers

  • Authors report no placebo arm, no double blinding, and subjective outcomes.
  • Bilateral feet from some participants were analyzed as independent units without adjustment for intra-person clustering.
  • Radiofrequency group had longer symptom duration at baseline; authors note possible confounding.
  • Patient counts in Results prose and Table 2 are inconsistent; exact arm participant totals remain unresolved.
  • No outcome beyond 12 months was assessed.
Research review

Source-linked critical reading

Randomized comparative clinical trial

Reading depthMaterial consulted
Technical source record

All 14 article section records, three structured tables with footnotes, four figure captions and disclosures reviewed. Raw XML table-wrap count (3) matches parsed tables. Figure pixels unavailable locally. Supplementary-information headings are present but no supplementary contents were included.

Review statusAI-assisted draft · independent automated checkThis automated check comes before the editor’s clinical review.
Design

Prospective three-arm randomized controlled trial. A computer-generated 1:1:1 sequence was prepared by an independent researcher, with group assignment concealed until intervention. The study planned 60 feet and reports final outcomes per foot.

Participants

Adults with heel pain for at least six months, symptoms despite at least two conservative treatments, and clinical plantar-fascia findings. The final results report 20 feet from 18 patients in the corticosteroid group, 19 feet from 15 patients in the ESWT group and 23 feet from 16 patients in the radiofrequency group. However, Table 2's female/male figures sum to 20, 19 and 23 respectively, matching the foot counts rather than the patient counts; counts are inconsistent. Some patients contributed both feet, analyzed independently.

Interventions

Corticosteroid group: ultrasound-guided medial injection of 1 mL betamethasone 40 mg/mL plus 2 mL bupivacaine 5 mg/mL. ESWT: BTL-5000 SWT, 15 Hz, 2,000 pulses, 4.0 bar, three weekly sessions, ultrasound guided. Radiofrequency thermal lesioning: single session under ultrasound guidance; NeuroTherm JK4A, 22G 10-cm cannula, 50 Hz, 90°C for 90 seconds at up to three pain sites; 1 mL 2% lidocaine at entry. All groups received five days of NSAIDs, ice advice and stretching; no weight-bearing restriction was advised.

Comparators

The three active treatments were compared directly. All groups received the same short course of NSAIDs and advice on ice and stretching; there was no placebo or untreated group.

Outcomes

Primary outcome was pain on a 10-cm VAS, anchored 0 (no pain) to 10 (worst imaginable). Other outcomes were Foot Function Index (FFI; total and pain, disability, activity-limitation components) and Roles and Maudsley score. Measurements occurred at baseline and months 1, 6 and 12. Table 3 reports group means, SDs and CIs; narrative reports post-hoc pairwise results.

Between-group findings

All groups improved from baseline. At 12 months, mean VAS was 1.61 (SD 0.839) radiofrequency, 3.47 (2.010) ESWT and 3.05 (1.432) corticosteroid. The authors report radiofrequency better than ESWT (p<0.001) and corticosteroid (p=0.006); the reported differences were 1.86 and 1.44 VAS points, respectively, exceeding the authors’ 1.2-point MCID. FFI total scores at 12 months were 27.043 (SD 12.4261), 56.737 (33.7505) and 50.250 (23.5816), respectively; radiofrequency was reported better than ESWT (p=0.001) and corticosteroid (p=0.008). Roles and Maudsley score favored radiofrequency at 12 months (p=0.002). No group difference was found for FFI pain component. These subjective outcomes require caution given lack of double blinding.

Harms

The article does not provide a structured adverse-event table or arm-level adverse-event counts. It discusses known corticosteroid risks such as fat-pad atrophy and plantar fascia rupture, but does not report study-specific event counts for the three arms.

Limitations

Authors note no placebo arm, lack of double blinding and subjective outcomes. Both feet from some participants were analyzed independently without adjustment for within-person clustering. Symptom duration was longer in radiofrequency group; authors note this may confound the apparent long-term advantage. The sample counts conflict between Results narrative and Table 2, so exact participant-level arm sizes are unresolved. Twelve-month follow-up does not establish longer-term outcome.

Applicability

Results suggest radiofrequency may offer greater improvement in selected outcomes at 12 months in this refractory cohort; they do not establish it as first-line therapy. The per-foot analysis and baseline symptom-duration imbalance may inflate apparent precision or affect comparison. ESWT was delivered at a stated 4.0 bar; no conversion to energy flux density is justified.

Further research

Authors call for larger double-blind placebo-controlled trials and longer follow-up. Future work should account for bilateral feet clustered within participants, report participant and foot counts consistently, and assess objective pain sensitivity alongside function.

THE ORIGINAL SOURCE

Read the original article.

Comparative efficacy of corticosteroid injection, extracorporeal shock wave therapy, and radiofrequency ablation for chronic plantar fasciitis: a prospective randomized controlled trial.

Tütüncü MN, Sekizkardeş M, Şahin E, Karaismailoğlu B. · BMC musculoskeletal disorders · 2026

Open the publication record or available full-text files.

Checked against the full paper · Clinical review: Dr. Marcus Yu Bin Pai, · How we review →